RWM
AMRX icon

Raffa Wealth Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Raffa Wealth Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$87 Buy
5
+4
+400% +$55 ﹤0.01% 1414
2026
Q1 		$12 Buy
+1
New +$13 ﹤0.01% 1501

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Raffa Wealth Management's AMRX Position: Q2 2026 in Review

Raffa Wealth Management increased its Amneal Pharmaceuticals (AMRX) stake by 400% in Q2 2026, buying an estimated $55 and bringing the position to 5 shares worth $87. The position accounts for ﹤0.01% of the portfolio, ranked #1414.

Raffa Wealth Management first reported a position in AMRX in Q1 2026 and has held it in 2 quarters since. 288 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Raffa Wealth Management held 5 shares of Amneal Pharmaceuticals worth $87 as of Q2 2026.
  • Raffa Wealth Management bought 4 Amneal Pharmaceuticals shares in Q2 2026, an estimated $55.
  • Amneal Pharmaceuticals made up ﹤0.01% of Raffa Wealth Management's portfolio in Q2 2026, its #1414 holding.
  • Raffa Wealth Management first reported a position in Amneal Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 288 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Raffa Wealth Management's 13F filing for Q2 2026, filed 27 Jul 2026.